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A B S T R A C T
Clinical studies suggest that outcomes for hospitalised malaria patients can be improved by managed hypothermia during treatment. We examined the impact of
short pulses of low temperature on ring-stage susceptibility of Plasmodium falciparum to artemisinin in vitro. The usually artemisinin-sensitive clone 3D7 exhibited
substantially reduced ring-stage susceptibility to a 4-h pulse of 700 nM dihydro-artemisinin administered during a 5-h pulse of low temperature down to 17 °C.
Parasite growth through the subsequent asexual cycle was not affected by the temperature pulse. Chloroquine and pyronaridine susceptibility, in a standard 48-h test,
was not affected by brief exposures to low temperature. Fever-like temperature pulses up to 40 °C were also accompanied by enhanced ring-stage survival of 700 nM
artemisinin pulses, but parasite growth was generally attenuated at this temperature. We discuss these findings in relation to the possible activation of parasite stress
responses, including the unfolded protein response, by hypo- or hyper-thermic conditions. Physiological states may need to be considered in artemisinin-treated P.
falciparum patients.
1. Introduction
Malaria remains a significant cause of disease and mortality
worldwide. Elimination efforts are complicated by developing drug
resistance to artemisinin combination therapies (ACT) by Plasmodium
falciparum in Southeast Asia. Though the genetic basis of this resistance
is clearly linked to mutations in pfkelch13, encoding a cytosolic protein
of generally unknown function, understanding the biochemical and
environmental effectors of parasite susceptibility to antimalarial drugs
remains an active avenue of research (Imwong et al., 2017; Noedl et al.,
2008; Ménard et al., 2016). The importance of this work is underscored
by sporadic evidence of ACT treatment failure across sub-Saharan
Africa, which seem to be occurring in the absence of pfkelch13 muta-
tions (Muwanguzi et al., 2016; Taylor et al., 2015). This is corroborated
by several recent reports of treatment failure in travellers infected with
P. falciparum after visiting the African continent (Sondén et al., 2017;
Sutherland et al., 2017).
When left inadequately treated, P. falciparum infections may pro-
gress to severe disease such as cerebral malaria, which in turn may
result in coma and death. Survivors frequently suffer measurable neu-
rological deficit during convalescence (Mishra and Newton, 2009; Idro
et al., 2016). A recent case report suggested the use of controlled hy-
pothermia (32-34 °C) improved the resolution of neurological con-
sequences of cerebral oedema and reduced cranial perfusion, as in other
vascular medical emergencies like heart attack and stroke (Gad et al.,
2018). Additionally, an in vitro model of mild hypothermia suggested
that this treatment may also potentiate certain frontline antimalarials
including artemisinin (Rehman et al., 2016).
Given a recent study which indicated that the cell stress response
underlies ring-stage artemisinin resistance (Zhang et al., 2017), and
evidence that temperature modulations induce a similar stress response
in higher eukaryotes (Lee et al., 2016; Rzechorzek et al., 2015a; Liu
et al., 2013; Kim et al., 2013; Xu et al., 2011), we sought to clarify the
impact of temperature variation on P. falciparum susceptibility to ar-
temisinin in the ring stage survival assay (RSA). Unlike the methods
used in previous studies, the in vitro readouts from this assay correlate
well with clinical treatment outcomes (Witkowski et al., 2013). Parasite
susceptibility to artemisinin in the early ring stage, within the first 7 h
post-invasion of a host erythrocyte, was investigated in an otherwise
artemisinin- and chloroquine-sensitive parasite background under
carefully calibrated exposures to both low and elevated temperatures
designed to mimic both hypothermia and fever cycles.
2. Materials and methods
2.1. Parasite culture
Plasmodium falciparum culture was performed in AB+ red blood cells
obtained from the UK Blood Bank. 3D7 parasites were cultured in RPMI
supplemented with Albumax II, L-glutamine, and gentamycin at 5%
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haematocrit under 5% CO2 conditions at 37 °C. Parasite cultures were
synchronised using 70% Percoll gradients to capture schizonts and 5%
sorbitol to selectively isolate ring-stage parasites.
2.2. Ring-stage survival assay (RSA4h)
Synchronised ring-stage cultures (0–2 h post-invasion) at 2% hae-
matocrit and 0.5% parasitaemia were exposed to 700 nM dihy-
droartemisinin (DHA) or equivalent DMSO for 4 h from 3 to 7 h post-
invasion. Infected cells were then washed five times in media before
being returned to culture. Survival at 72 h post-invasion was measured
using a flow cytometry protocol based on published methods (Yang
et al., 2016). Briefly, infected cells were incubated with 8 vol of FACS-
stain solution (SYBR Green (1:1000; Invitrogen), MitoTracker Deep Red
(1:10,000; Invitrogen) in PBS) for 20min at 37 °C. Parasite proliferation
was determined by FACS (LSR-II flow cytometer, BD Biosciences), as
previously described (Yang et al., 2016). Ring-stage survival was
quantified as the ratio of SYBR+/MTDR+ DHA-treated to DMSO-
treated events.
For temperature-variant RSA experiments, synchronised cultures
were pre-incubated at the experimental temperature from hours 2–3
post-invasion before being treated with DHA or DMSO, with continued
incubation at the experimental temperature during the drug pulse from
hours 3–7 post-invasion. After this pulse, infected cells were washed
with media pre-warmed to 37 °C and returned to culture at 37 °C until
FACS was performed. RSA experiments were performed in technical
duplicate, with each replicate enumerating at least 100,000 gate-stop-
ping events. The mean of at least three biological replicates is presented
with standard error. The temperature pulse was thus 5 h, and the drug
pulse 4 h in duration, nested within the temperature pulse. Data were
analysed in Graph Pad Prism 7. Significance was determined by analysis
of variance (ANOVA), with correction for inter-experiment and intra-
experiment variance. Pairwise comparisons between 37 °C and the
lowest temperature tested, and between 37 °C and the highest tem-
perature tested were statistically evaluated by the t-test of Student.
2.3. Chloroquine and pyronaridine 48 h susceptibility assays
Susceptibility to these two drugs was determined by incubating
parasites in serial dilutions of chloroquine or pyronaridine at 2% hae-
matocrit and 0.5% parasitaemia in 96-well plates. These plates were
incubated at experimental temperatures during the same temperature
window described above and returned to 37 °C incubation after this
transient temperature modulation. After 48 h, parasite proliferation in
these plates was quantitated using SYBR Green as previously described
(van Schalkwyk et al., 2017). Each experiment was performed in
technical duplicate. The mean EC50 of at least three biological replicates
is presented with standard error.
3. Results
3.1. Transient temperature variation affects ring-stage artemisinin
susceptibility in vitro
The dependence on environmental temperature of ring-stage sus-
ceptibility to artemisinin was examined by transiently exposing pfk13
wild-type 3D7 parasites to a range of temperatures before and during
the RSA4h. Given previous data suggesting hypothermic conditions (32-
34 °C) could enhance anti-plasmodial effects of artemisinin in vitro,
estimated as EC50 in a full life-cycle assay (Rehman et al., 2016), we
probed a range of low temperatures (17ºC-36 °C) alongside nor-
mothermic (37 °C) conditions in parallel. In contrast to these previous
results, our data suggest that environmental temperature and ring-stage
artemisinin susceptibility in the 3D7 reference parasite line are nega-
tively correlated in vitro (Fig. 1A) (Gad et al., 2018). In the RSA, re-
duced susceptibility to artemisinin is expressed as enhanced survival
following a pulse of 700 nM DHA, compared to known susceptible
parasites. Surprisingly, 3D7 parasite survival in the RSA was enhanced
by transient hypothermic incubations immediately post-invasion, ex-
ceeding 20% at temperature pulses below 25 °C, rising to almost 50%
survival at 17 °C (Fig. 1A). By ANOVA, RSA survival was significantly
associated with falling temperature, after correction for inter- and intra-
experiment variation (P < 0.001; 63 d.f.). By comparison, parasites
harbouring the R539T pfkelch13 mutation conferring reduced suscept-
ibility to artemisinin in Southeast Asia display survival rates of
28 ± 2.4% in our assay format under normothermic conditions
(Fig. 1A), similar to published estimates (Yang et al., 2016). These
transient exposures to hypothermic environments had no significant
effect on parasite proliferation in the absence of drug (Fig. 1B) and did
not affect susceptibility to chloroquine in a standard EC50 assay with
48-h drug exposure (Fig. 1C).
To compare our findings of reduced artemisinin susceptibility in the
hypothermic RSA with another drug thought to display some ring-stage
activity (Chen et al., 1987), we generated EC50 estimates for
Fig. 1. Effect of transient hypothermia on ring-stage artemisinin susceptibility of P. falciparum (3D7). A. Ring-stage survival (proportion of control) of DHA
pulse-treated 3D7 parasites (black circles) transiently incubated at hypothermic and normothermic temperatures. Open circles represent RSA survival estimates, in
our hands, for previously described Cambodian parasite lines Cam 3.11 (reduced DHA susceptibility) and Cam 3.11REV (fully DHA susceptible) (Straimer et al., 2014),
with corresponding K13 genotypes in superscript. P value was estimated by two-sided t-test between 17 °C (n= 4) and 37 °C (n=6) (mean difference 58.7% survival;
95% CI 57.7–59.8% survival; 8 d.f.).B. Effects of temperature modulation on 3D7 parasite proliferation in the absence of drug. Relative drug-free parasitaemia of
temperature-pulsed parasite cultures was measured 72 h post-invasion as a proportion of the parasitaemia of parallel cultures incubated at 37 °C for the duration of
the experiment. Each data point in A and B represents the mean of at least four biological replicates at each temperature, each performed in technical duplicate, with
standard error. Each technical replicate enumerates at least 100,000 gate-stopping events by flow cytometry.C. Effects of transient (3–7 h post-invasion) incubation at
hypothermic temperature on parasite susceptibility to a 48-h exposure to chloroquine.
Mean of at least three biological replicates is shown, each performed in technical duplicate; standard error is shown.
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pyronaridine acting upon 3D7 parasite cultures synchronised as de-
scribed for the RSA experiments, with and without incubation at low
temperature during early ring-stage development, and with and
without a drug wash-out at 7 h post-invasion (Table 1). Exposure to low
temperature during early ring-stage development had no impact on
parasites exposed to pyronaridine for a full life-cycle, and a minor
impact when drug was washed out at 7 h; this was not statistically
significant (Table 1).
In clinical infections, fevers are triggered by schizont egress, and
therefore, fever conditions overlap with the window of ring-stage de-
velopment when reduced susceptibility to artemisinin is known to
occur. Given these striking results under hypothermia, we wondered
whether hyperthermic environments mimicking fever conditions had a
similar inhibitory effect on ring-stage susceptibility to artemisinin. To
this end, we examined a range of hyperthermic conditions from 38 to
41 °C. As seen for the hypothermia experiments, a statistically sig-
nificant increase in RSA survival was observed (Fig. 2A; ANOVA
P < 0.001, 14 d.f.), though conditions exceeding 39 °C strongly in-
hibited parasite proliferation in the absence of drug (Fig. 2B), as pre-
viously reported (Rehman et al., 2016; Chen et al., 1987). Ring-stage
survival was not estimated for parasites treated with a 41 °C pulse be-
cause this killed nearly all mock-treated cells. Parasite susceptibility to
chloroquine in the standard 48-h exposure assay was unaffected by the
transient raised temperature (Fig. 2C).
4. Discussion
Fever cycles, important symptomatic manifestations of malaria in-
fection, coincide with significant chemical and immunological changes
to the host environment. However, the impacts of these transient
temperature fluctuations on parasite development and antimalarial
susceptibility are relatively unclear. The results of this study suggest
that ring-stage parasite susceptibility to artemisinin derivatives may be
exquisitely sensitive to environmental temperature even in the absence
of pfkelch13 mutations. Parasite susceptibility to DHA is slightly re-
duced under transient fever conditions, approaching 10% survival in
the RSA. In contrast, parasite ring-stage susceptibility to DHA is dra-
matically reduced in a temperature-dependent manner with transient
pulses below 30 °C, while not directly affecting parasite survival across
the full life cycle per se. We see no impact of transient hypothermia on
susceptibility to the unrelated comparator drug chloroquine, assessed
with the standard 48-h readout for aminoquinolines, and a minimal
EC50 increase for pyronaridine when drug was washed out at 7 h post-
invasion. This increase was non-significant, and the drug remained
highly potent (median EC50 32.6 nM). Future studies could explore the
effects of transient hypothermia or other cell stresses on ring-stage
activity of other antimalarial drug classes.
It is unclear whether in vitro RSA outcomes are reliable predictors of
clinical outcomes. However, these results show that hypothermic con-
ditions, under exploration for the co-treatment of severe malaria pa-
tients, moderately attenuate artemisinin ring-stage cytotoxicity in vitro.
As this study specifically examined the effects of transient decreases in
environmental temperature, it is likely that the anti-plasmodial effects
of continuous hypothermia override the brief contribution of these
conditions to reducing ring-stage artemisinin susceptibility (Rehman
et al., 2016). As reported previously (Rehman et al., 2016; Long et al.,
2001), in our hands hyperthermia exerts strong anti-plasmodial effects
on ring-stage cultures, even under transient fever conditions.
Unravelling the mechanisms behind these observations is beyond
the scope of this study. The thermodynamics of artemisinin activation
and cellular development are unlikely to completely explain these re-
sults. The oxidative opening of the critical endoperoxide bridge in the
artemisinin molecule is likely a temperature-dependent process. Under
hypothermic conditions, the rate of this opening may be slower and
therefore could contribute to the reduced susceptibility of cells under
hypothermia. However, under this explanation hyperthermia should be
Table 1
Impact of a 4-h pulse of low temperaturea on pyronaridine EC50 estimatesb for 3D7 parasites, with and without a drug wash-out.
Median Pyronaridine EC50 (IQR) Constant 37 °C (n=5, 5) 18–19 °C 2–7 h post-invasion, then 37 °C (n= 5, 4)c P valued
48 h continual drug exposure 5.15 nM (1.21–7.87 nM) 3.91 nM (1.17–13.16 nM) 0.50
3–7 h post-invasion, washed out 14.03 nM (1.92–15.51 nM) 32.64 nM (20.95–37.01 nM) 0.065
h: hour.
a Ambient room temperatures used for the 5 experiments performed were 18, 18, 19, 18 and 19 °C, respectively.
b A full dose-response curve was generated for each treatment, in five experiments each in technical duplicate.
c Meaningful data were obtained for only 4 of 5 experiments in the temperature-pulsed, drug pulsed treatment.
d Paired sign test, one-sided (Ho: 18 °C increases EC50.).
Fig. 2. Effect of transient hyperthermia
on ring-stage artemisinin susceptibility
of P. falciparum (3D7). A. Ring-stage sur-
vival (proportion of control) of DHA pulse-
treated parasites transiently incubated at
normothermic and hyperthermic tempera-
tures. The data represent 15 RSA survival
estimates, with 3 technical replicates for
each timepoint above 37 °C. P value from
two-sided t-test between 40.2 °C (n= 3)
and 37 °C (n= 6) (mean difference 7.73%
survival; 95% CI 6.56–8.90% survival; 7
d.f.).B. Effects of temperature modulation
on parasite proliferation in the absence of
drug. Relative drug-free parasitaemia mea-
sured 72 h post-invasion as a percentage of
the parasitaemia of replicates incubated at
37 °C. Each data point in A and B represents
the mean of at least three biological replicates at each temperature, each performed in technical duplicate, with standard error. Each technical replicate enumerates
at least 100,000 gate-stopping events by flow cytometry.C. Effects of transient (3–7 h post-invasion) incubation at hyperthermic conditions on parasite susceptibility
to a 48-h exposure to chloroquine.
Mean of at least three biological replicates is shown with standard error.
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correlated with enhanced susceptibility, yet we observe the opposite.
Likewise, if hypothermic conditions slow parasite development, this
might be expected to elicit an extension of the ring stage, known to be
hypersensitive to artemisinin in wild-type parasites (Klonis et al.,
2013). Additionally, since hyperthermia exerts anti-plasmodial effects,
one might expect increasing temperature to decrease the fractional
inhibitory concentration of artemisinin required to sterilise the culture.
However, we again observe the opposite.
Previous results have shown that the cell stress response underlies
reduced ring-stage artemisinin susceptibility in P. falciparum (Zhang
et al., 2017). Hyperthermia and hypothermia are known to trigger this
mechanism in mammalian cells by destabilising proteins and slowing
protein folding and translation, respectively (Lee et al., 2016; Kim et al.,
2013; Xu et al., 2011; Rzechorzek et al., 2015b). Therefore, it is possible
that a similar cell stress response is triggered in malaria parasites by
these environmental modulations. This requires further investigation.
To date, attempts to understand the cellular mechanism of artemi-
sinin resistance have started from the vantage point afforded by
pfkelch13 mutations. However, the results from this and previous stu-
dies suggest that the role of K13 is underpinned by fundamental me-
chanisms that may be mobilised independently to cause resistance
(Zhang et al., 2017; Mok et al., 2015; Bhattacharjee et al., 2018). These
results highlight a new approach to studying the ring-stage artemisinin
resistance phenotype and underscore the potential importance of the
physiologic environment upon the outcome of antimalarial assays,
particularly with short-lived drugs like artemisinin. Lastly, our findings
should be considered when planning future studies to evaluate the
impacts of mild hypothermia on the treatment of severe malaria pa-
tients with artemisinin derivatives, as these effects may be parasite-
stage dependent.
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